 |
Vol.59 No.3 contents | Japanese/English |
 | Full Text of PDF (523K) Article in Japanese |
- INVITED REVIEW ARTICLE -
Mechanisms of Resistance to Molecular-targeted Drugs in Lung Cancer
Ryohei Katayama11Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Japan
In lung adenocarcinoma, which accounts for about 60% of lung cancer cases, remarkable therapeutic effects have seen due to the discovery of driver oncogenes, such as EGFR mutations and ALK fusion gene, and the development of corresponding molecular-targeted drugs. However, acquired resistance remains an issue that is difficult to overcome. In this review, we will discuss the latest research findings concerning mechanisms underlying resistance to molecular-targeted drugs and potential therapeutic strategies for overcoming such resistance in driver oncogene-positive lung cancer.
key words: EGFR, ALK fusion gene, Resistance mutation, Gatekeeper mutation, Compound mutation
JJLC 59 (3): 224-230, 2019
